4.7 Article

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

期刊

KIDNEY INTERNATIONAL
卷 95, 期 6, 页码 1304-1317

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2019.02.022

关键词

cardiovascular disease; chronic kidney disease; congestive heart failure; hemodialysis; transplantation

资金

  1. KDIGO
  2. Abbott
  3. Akebia Therapeutics
  4. AMAG Pharmaceuticals
  5. Amgen
  6. AstraZeneca
  7. Boehringer Ingelheim
  8. Corvidia
  9. Fresenius Medical Care
  10. Keryx Biopharmaceuticals
  11. NxStage
  12. Relypsa
  13. Roche
  14. Sanifit
  15. Vifor Fresenius Medical Care Renal Pharma

向作者/读者索取更多资源

The incidence and prevalence of heart failure (HF) and chronic kidney disease (CKD) are increasing, and as such a better understanding of the interface between both conditions is imperative for developing optimal strategies for their detection, prevention, diagnosis, and management. To this end, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference titled Heart Failure in CKD. Breakout group discussions included (i) HF with preserved ejection fraction (HFpEF) and nondialysis CKD, (ii) HF with reduced ejection fraction (HFrEF) and nondialysis CKD, (iii) HFpEF and dialysis-dependent CKD, (iv) HFrEF and dialysis-dependent CKD, and (v) HF in kidney transplant patients. The questions that formed the basis of discussions are available on the KDIGO website http://kdigo.org/conference/heart-failure-in-ckd/, and the deliberations from the conference are summarized here.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据